ES2178205T3 - Compuestos amida indazol como agentes serotoninergicos. - Google Patents

Compuestos amida indazol como agentes serotoninergicos.

Info

Publication number
ES2178205T3
ES2178205T3 ES98919257T ES98919257T ES2178205T3 ES 2178205 T3 ES2178205 T3 ES 2178205T3 ES 98919257 T ES98919257 T ES 98919257T ES 98919257 T ES98919257 T ES 98919257T ES 2178205 T3 ES2178205 T3 ES 2178205T3
Authority
ES
Spain
Prior art keywords
sup
amida
compound
serotoninergic agents
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98919257T
Other languages
English (en)
Inventor
Alessandra Alisi
Mario Brufani
Nicola Cazzolla
Marilena Giannangeli
Mario Pinza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Application granted granted Critical
Publication of ES2178205T3 publication Critical patent/ES2178205T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La invención tiene por objeto un compuesto que tiene fórmula general (I) en la que R{sup,1}, R{sup,2} R{sup,3 } R''{sup,3} R{sup,4} R{sup,5} y R{sup,6} tienen el significado indicado en la descripción, la invención se refiere igualmente a sales de adicción ácidas de éste compuesto con ácidos orgánicos o inorgánicos farmacéuticamente aceptables y de las sales cuaternarias farmacéuticamente aceptables de éste compuesto.
ES98919257T 1997-04-15 1998-04-02 Compuestos amida indazol como agentes serotoninergicos. Expired - Lifetime ES2178205T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI000867A IT1291569B1 (it) 1997-04-15 1997-04-15 Indazolammidi come agenti serotoninergici

Publications (1)

Publication Number Publication Date
ES2178205T3 true ES2178205T3 (es) 2002-12-16

Family

ID=11376888

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98919257T Expired - Lifetime ES2178205T3 (es) 1997-04-15 1998-04-02 Compuestos amida indazol como agentes serotoninergicos.

Country Status (27)

Country Link
US (1) US6197769B1 (es)
EP (1) EP0975623B1 (es)
JP (2) JP4578581B2 (es)
KR (1) KR100563867B1 (es)
CN (1) CN1318416C (es)
AR (1) AR012426A1 (es)
AT (1) ATE219490T1 (es)
AU (1) AU740360B2 (es)
BG (1) BG64006B1 (es)
CA (1) CA2286870C (es)
CZ (1) CZ295190B6 (es)
DE (1) DE69806141T2 (es)
DK (1) DK0975623T3 (es)
EA (1) EA002352B1 (es)
ES (1) ES2178205T3 (es)
GE (1) GEP20022654B (es)
HK (1) HK1027811A1 (es)
HU (1) HU227973B1 (es)
IL (1) IL132127A (es)
IT (1) IT1291569B1 (es)
PL (1) PL193308B1 (es)
PT (1) PT975623E (es)
SK (1) SK284731B6 (es)
TR (1) TR199902546T2 (es)
UA (1) UA58550C2 (es)
WO (1) WO1998046589A2 (es)
ZA (1) ZA982926B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
KR100849839B1 (ko) 2001-02-23 2008-08-01 머크 앤드 캄파니 인코포레이티드 Ｎ-치환된 비-아릴-헤테로사이클릭 ｎｍｄａ/ｎｒ2ｂ 길항제 및 이를 포함하는 약제학적 조성물
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) * 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
ITMI20031468A1 (it) * 2003-07-18 2005-01-19 Acraf Farmaco ativo nel dolore neuropatico
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
DE602005016446D1 (de) * 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
ATE431824T1 (de) * 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
CN101080406A (zh) * 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物
JP2008530225A (ja) * 2005-02-17 2008-08-07 セラヴァンス， インコーポレーテッド インダゾール−カルボキサミド化合物の結晶型
JP5042043B2 (ja) * 2005-03-02 2012-10-03 セラヴァンス， インコーポレーテッド ５−ｈｔ４レセプターアゴニストであるキノリン化合物
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
UA99927C2 (uk) * 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
KR20140041519A (ko) * 2011-06-07 2014-04-04 다이닛본 스미토모 세이야꾸 가부시끼가이샤 인다졸-유도체 및 피롤로피리딘-유도체 및 그의 약제학적 용도
CN104080781B (zh) * 2012-02-21 2016-05-11 方济各安吉利克化学联合股份有限公司 1H-吲唑-3-甲酰胺化合物作为糖原合酶激酶3β抑制剂的用途
HUE026893T2 (en) * 2012-02-21 2016-07-28 Acraf 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3-beta inhibitors
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
AU2020311942A1 (en) 2019-07-11 2022-02-24 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US5945434A (en) * 1995-05-31 1999-08-31 Nisshin Flour Milling Co., Ltd. Indazole derivatives having monocyclic amine
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici

Also Published As

Publication number Publication date
EA002352B1 (ru) 2002-04-25
CN1318416C (zh) 2007-05-30
JP4578581B2 (ja) 2010-11-10
ATE219490T1 (de) 2002-07-15
AU7215998A (en) 1998-11-11
IL132127A (en) 2005-06-19
PT975623E (pt) 2002-10-31
CA2286870C (en) 2007-05-22
US6197769B1 (en) 2001-03-06
HU227973B1 (hu) 2012-07-30
CZ362599A3 (cs) 2000-04-12
SK142399A3 (en) 2000-08-14
KR20010006120A (ko) 2001-01-26
PL336348A1 (en) 2000-06-19
AU740360B2 (en) 2001-11-01
ITMI970867A1 (it) 1998-10-15
IT1291569B1 (it) 1999-01-11
IL132127A0 (en) 2001-03-19
EP0975623A2 (en) 2000-02-02
TR199902546T2 (xx) 2000-05-22
KR100563867B1 (ko) 2006-03-24
DK0975623T3 (da) 2002-10-14
UA58550C2 (uk) 2003-08-15
GEP20022654B (en) 2002-03-25
HUP0002057A2 (hu) 2001-04-28
EA199900935A1 (ru) 2000-04-24
HK1027811A1 (en) 2001-01-23
BG64006B1 (bg) 2003-09-30
DE69806141D1 (de) 2002-07-25
BG103863A (en) 2000-07-31
SK284731B6 (sk) 2005-10-06
WO1998046589A3 (en) 1999-01-28
HUP0002057A3 (en) 2002-01-28
DE69806141T2 (de) 2003-01-30
CA2286870A1 (en) 1998-10-22
JP5237324B2 (ja) 2013-07-17
CN1252798A (zh) 2000-05-10
CZ295190B6 (cs) 2005-06-15
AR012426A1 (es) 2000-10-18
WO1998046589A2 (en) 1998-10-22
JP2001518906A (ja) 2001-10-16
EP0975623B1 (en) 2002-06-19
ZA982926B (en) 1998-10-09
PL193308B1 (pl) 2007-01-31
JP2010195813A (ja) 2010-09-09

Similar Documents

Publication Publication Date Title
ES2178205T3 (es) Compuestos amida indazol como agentes serotoninergicos.
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
PA8436201A1 (es) Derivados 6,5-heterobiciclicos sustituidos
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
ES2193208T3 (es) Nuevos derivados de quinuclidina y composicion farmaceutica que los contiene.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
ES2162198T3 (es) Agentes estrogenos.
ES2123287T3 (es) Derivados 3-benzoil benzofuranicos como antagonistas de la hormona tiroidea.
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
GT200100232A (es) Derivados de pirimidina.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
ES2144034T3 (es) Composiciones farmaceuticas estables que contienen alfa-interferon hibrido.
DE69823240D1 (de) Immunmodulierende arzneimittelzusammenstellung
ES2182086T3 (es) Nuevos derivados de peptidil-arginina aldehido.
ES2191763T3 (es) Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.
UY26329A1 (es) Antagonistas de los receptores de vitronectina
PA8429501A1 (es) Derivados de acido 3-aributirico sustituido como inhibidores de la metaloproteasa de matriz
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
BR9813775A (pt) Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular.